U.S. Trade Representative Jamieson Greer launched a Section 301 trade investigation into Germany's pharmaceutical pricing policy on June 18, 2026 [1].
The move signals a potential escalation in trade tensions between Washington and Berlin over the accessibility and profitability of American-made medicines. Because the pharmaceutical industry is a cornerstone of U.S. exports, any policy deemed discriminatory could lead to tariffs or other trade sanctions.
The investigation aims to assess whether Germany's approach to drug pricing is unreasonable or discriminatory toward American innovators [2]. Under Section 301 of the Trade Act of 1974, the U.S. government can investigate foreign trade practices that are believed to burden U.S. commerce. The probe will examine if German regulations unfairly target U.S. companies or create an uneven playing field for domestic firms.
U.S. officials have specifically pointed to Germany's health-care spending cuts, which are cited as $23 billion [3]. This reduction in spending is viewed by the U.S. as a factor that may harm U.S. interests by limiting the revenue American pharmaceutical companies can generate within the German market.
Jamieson Greer said the investigation is necessary to determine if these measures are harmful to U.S. interests. The process typically involves a period of public comment, and consultation with affected industries, before the Trade Representative decides whether to impose retaliatory measures.
Germany has not yet issued a formal response to the launch of the probe. However, the investigation puts pressure on Berlin to justify its pricing models as the U.S. continues to prioritize the protection of intellectual property and market access for its high-tech sectors.
“The investigation aims to assess whether Germany's approach to drug pricing is unreasonable or discriminatory.”
This investigation represents a strategic use of Section 301 to leverage trade pressure in exchange for more favorable pricing for U.S. pharmaceuticals. By framing health-care spending cuts as a trade barrier, the U.S. is shifting a public-health policy dispute into a commercial conflict, which could lead to retaliatory tariffs if a resolution is not reached.
